A Clinical Study That Will Meaure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anixety Disorder
Study Details
Study Description
Brief Summary
A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old. The study will be held in Approximately 50 global study centers and approximately 15 additional centers for a separate Japan population. Participation in the study can be up to approximately 12 weeks.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2/Phase 3 |
Detailed Description
This is a multicenter, randomized, double-blind, parallel-group, flexible dose, outpatient study evaluating the efficacy and safety of SEP-363856 flexibly dosed (50 - 75 mg/day) versus placebo over an 8-week Treatment Period in subjects with GAD. This study is projected to randomize approximately 434 subjects to 2 treatment groups (SEP-363856 [50 - 75 mg/day] or placebo) in a 1:1 ratio.
Approximately 30 additional subjects (N = 15 per treatment group) are projected to enroll in the Japan Cohort. Treatment assignment will be stratified by country. Study drug will be taken at approximately the same time each evening at bedtime .
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: SEP-363856 dosed once daily tablet |
Drug: SEP-363856
once daily tablet
|
| Placebo Comparator: Placebo dosed once daily tablet |
Drug: Placebo
once daily tablet
|
Outcome Measures
Primary Outcome Measures
- Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Endpoint [Week 8]
The HAM-A scale consists of 14 items, each defined by a series of symptoms. Each item is rated on a 5-point (0-4) scale, with higher scores indicating greater severity.
Secondary Outcome Measures
- Change from Baseline in Clinical Global Impression-Severity (CGI-S) score at Endpoint [Week 8]
The CGI-S is a clinician-rated assessment of the subject's current illness state on a 7-point scale, where a higher score is associated with greater illness severity.
Eligibility Criteria
Criteria
Inclusion Criteria: (list is not all inclusive)
-
Male or female subject between 18 to 65 years of age.
-
Subject meets DSM-5 criteria for a diagnosis of Generalized Anxiety Disorder.
-
Subject must be willing and able to comply with the study procedures and visit schedule and must be able to understand and follow verbal and written instructions.
Exclusion Criteria: (list is not all inclusvie)
-
Subject has a current DSM-5 diagnosis or presence of symptoms consistent with a major psychiatric disorder, other than Generalized Anxiety Disorder, that is the primary focus of treatment.
-
Subjects who report an inadequate response to more than 3 antidepressant treatments
-
Subject is at significant risk of harming self or others based on Investigator's judgment.
-
Subject has any clinically significant unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in the study.
-
Female subject who is pregnant, lactating, or plans to get pregnant during the study.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Sunovion
Investigators
- Study Chair: CNS Medical Director, Sunovion
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SEP361-226
- 2022-502077-42-00